Stocksigma LogoStocksigma Logo

GSK Pharmaceuticals Reports Q2 FY27 Consolidated Results and Leadership Changes

GlaxoSmithKline Pharmaceuticals reported consolidated revenue from operations of ₹1,183.57 crore for the quarter ended 30th Sep'26, up 20.78% YoY from

GSK Pharmaceuticals Reports Q2 FY27 Consolidated Results and Leadership Changes

GlaxoSmithKline Pharmaceuticals Ltd · Change in Auditor · 04 Nov 2026, 12:31 am

GSK Pharmaceuticals Reports Q2 FY27 Consolidated Results and Leadership Changes GlaxoSmithKline Pharmaceuticals reported consolidated revenue from operations of ₹1,183.57 crore for the quarter ended 30th Sep'26, up 20.78% YoY from ₹979.94 crore. Consolidated net profit rose 30.44% YoY to ₹335.88 crore, supported by other income of ₹72.78 crore (including ₹42.09 crore interest on tax refund). Diluted EPS stood at ₹19.83. Additionally, the board approved the appointment of Sandeep Seth as Head – Ethics & Compliance and proposed Walker Chandiok & Co LLP as Statutory Auditors for five years starting FY28.

Original exchange filing (PDF)

More announcements from GlaxoSmithKline Pharmaceuticals Ltd

All GlaxoSmithKline Pharmaceuticals Ltd announcements